Hepatitis C Virus Elimination by 2030: Conquering Mount Improbable
Radha K. Dhiman, Madhumita Premkumar – 24 May 2021
Heterogeneidad clínica y virológica de la hepatitis delta en la Amazonia: más preguntas que respuestas
Raymundo Paraná, y Flor H. Pujol – 24 May 2021
Affordability of Antiviral Therapy in Asia‐Pacific Countries and Its Impact on Public Health Outcomes
Prowpanga Udompap, Tawesak Tanwandee, Rino Gani – 24 May 2021
PBC: No Longer a Western Disease?
Atsushi Tanaka – 24 May 2021
Insuficiencia hepática aguda secundaria a fiebre amarilla: un escenario complejo
Alice Tung Wan Song, y Luiz Augusto Carneiro D'Albuquerque – 24 May 2021
Preface: A CLD Collaboration With the Latin American Association for the Study of the Liver (ALEH)
Mário G. Pessoa, Manuel Mendizabal – 24 May 2021
Introduction: Liver Disease in Asia
Kazuhiko Koike, W. Ray Kim – 24 May 2021
Toward Norepinephrine as a First‐Line Treatment for All Hospitalized Patients With Hepatorenal Syndrome
Cary H. Paine, Raimund H. Pichler, Laura Evans, Scott W. Biggins – 23 May 2021
AASLD Deepens Commitment to Diversity, Equity, and Inclusion
Miguel Malespin, Elizabeth J. May, Lauren D. Nephew, Sonali Paul, Alexis McCary, Saikiran Kilaru, Nizar A. Mukhtar, Mohamed A. Hassan, Carla W. Brady – 23 May 2021
AASLD Deepens Commitment to Diversity, Equity, and Inclusion
Miguel Malespin, Elizabeth J. May, Lauren D. Nephew, Sonali Paul, Alexis McCary, Saikiran Kilaru, Nizar A. Mukhtar, Mohamed A. Hassan, Carla W. Brady – 23 May 2021